The goals of the Virology Core are to enhance the research capacity of the UNC CFAR research community by providing access to state-of-the-art tools for diagnosis and monitoring HIV+ patients in clinical trials, and providing leadership to promote HIV/AIDS research in this area through collaboration, training, and mentoring.
The specific aims are to 1) provide quality viral assays and services, 2) provide training and mentorship to the domestic and international CFAR community and build capacity at international sites, 3) provide leadership through activities locally, nationally, and internationally, 4) support NIH networks and CFAR-CFAR collaborations by participating in CHAVI, HPTN, IMPAACT, and ACTG, 5) support new CFAR initiatives through collaborations with UNC CFAR members, and 6) engage in evaluation and strategic planning, using input from user surveys, an Internal Advisory Board, and the CFAR External Advisory Board. Through these activities, the Virology Core will continue to provide key infrastructure support for the HIV/AIDS research activity of the CFAR membership. These activities will have a significant impact on the future of the epidemic by providing HIV, HCV, and HPV viral assays, including ultra-low copy number and POC assays, training and mentoring new US and international scientists, and providing leadership locally, nationally, and globally.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
2P30AI050410-14
Application #
8329988
Study Section
Special Emphasis Panel (ZAI1-ELB-A (J1))
Project Start
2011-08-01
Project End
2016-07-31
Budget Start
2011-08-01
Budget End
2012-07-31
Support Year
14
Fiscal Year
2011
Total Cost
$223,353
Indirect Cost
Name
University of North Carolina Chapel Hill
Department
Type
DUNS #
608195277
City
Chapel Hill
State
NC
Country
United States
Zip Code
27599
Wallace, Deshira D; Pack, Allison; Uhrig Castonguay, Breana et al. (2018) Validity of Social Support Scales Utilized Among HIV-Infected and HIV-Affected Populations: A Systematic Review. AIDS Behav :
Martin, Maureen P; Naranbhai, Vivek; Shea, Patrick R et al. (2018) Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1. J Clin Invest 128:1903-1912
Tucker, Joseph D; Fenton, Kevin A (2018) Innovation challenge contests to enhance HIV responses. Lancet HIV 5:e113-e115
Fitzpatrick, Thomas; Zhou, Kali; Cheng, Yu et al. (2018) A crowdsourced intervention to promote hepatitis B and C testing among men who have sex with men in China: study protocol for a nationwide online randomized controlled trial. BMC Infect Dis 18:489
Chinula, Lameck; Nelson, Julie A E; Wiener, Jeffrey et al. (2018) Effect of the depot medroxyprogesterone acetate injectable and levonorgestrel implant on HIV genital shedding: a randomized trial. Contraception 98:193-198
Fitzpatrick, Thomas; Pan, Stephen W; Tang, Weiming et al. (2018) HBV and HCV test uptake and correlates among men who have sex with men in China: a nationwide cross-sectional online survey. Sex Transm Infect 94:502-507
Rucinski, Katherine B; Rutstein, Sarah E; Powers, Kimberly A et al. (2018) Sustained Sexual Behavior Change After Acute HIV Diagnosis in Malawi. Sex Transm Dis 45:741-746
Mathews, Allison; Farley, Samantha; Hightow-Weidman, Lisa et al. (2018) Crowdsourcing and community engagement: a qualitative analysis of the 2BeatHIV contest. J Virus Erad 4:30-36
Curtis 2nd, Alan D; Jensen, Kara; Van Rompay, Koen K A et al. (2018) A simultaneous oral and intramuscular prime/sublingual boost with a DNA/Modified Vaccinia Ankara viral vector-based vaccine induces simian immunodeficiency virus-specific systemic and mucosal immune responses in juvenile rhesus macaques. J Med Primatol 47:288-297
Yanik, Elizabeth L; Hernández-Ramírez, Raúl U; Qin, Li et al. (2018) Brief Report: Cutaneous Melanoma Risk Among People With HIV in the United States and Canada. J Acquir Immune Defic Syndr 78:499-504

Showing the most recent 10 out of 1688 publications